Ken Griffin Cellectis S.A. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cellectis S.A. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,900 shares of CLLS stock, worth $9,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,900

Previous 2,800 110.71%

Holding current value

$9,322

Previous $5,000 140.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.9 - $2.4 $1,757 - $2,220	925 Added 3.46%	27,624 $58,000
Q2 2024 Aug 14, 2024	BUY	$1.86 - $3.35 $49,660 - $89,441	26,699 New	26,699 $49,000
Q4 2023 Feb 14, 2024	SELL	$0.97 - $3.55 $16,020 - $58,631	-16,516 Reduced 48.15%	17,784 $54,000
Q3 2023 Nov 14, 2023	BUY	$1.58 - $2.86 $6,820 - $12,346	4,317 Added 14.4%	34,300 $54,000
Q2 2023 Aug 14, 2023	BUY	$1.72 - $2.12 $51,570 - $63,563	29,983 New	29,983 $59,000
Q4 2022 Feb 14, 2023	BUY	$1.85 - $2.6 $84,820 - $119,207	45,849 Added 371.01%	58,207 $122,000
Q3 2022 Nov 14, 2022	SELL	$2.29 - $4.08 $25,718 - $45,822	-11,231 Reduced 47.61%	12,358 $28,000
Q2 2022 Aug 15, 2022	SELL	$2.39 - $4.93 $45,001 - $92,826	-18,829 Reduced 44.39%	23,589 $67,000
Q4 2021 Feb 14, 2022	BUY	$8.01 - $12.84 $10,148 - $16,268	1,267 Added 3.08%	42,418 $344,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $332,672 - $448,299	27,862 Added 209.66%	41,151 $519,000
Q2 2021 Aug 16, 2021	SELL	$14.36 - $20.93 $372,326 - $542,673	-25,928 Reduced 66.11%	13,289 $205,000
Q1 2021 May 17, 2021	BUY	$18.19 - $33.25 $442,471 - $808,806	24,325 Added 163.34%	39,217 $793,000
Q4 2020 Feb 16, 2021	SELL	$15.87 - $31.64 $363,248 - $724,207	-22,889 Reduced 60.58%	14,892 $403,000
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $2.1 Million - $2.78 Million	-133,498 Reduced 77.94%	37,781 $699,000
Q2 2020 Aug 14, 2020	SELL	$8.21 - $21.02 $695,789 - $1.78 Million	-84,749 Reduced 33.1%	171,279 $3.05 Million
Q1 2020 May 15, 2020	SELL	$7.81 - $18.82 $1.89 Million - $4.56 Million	-242,403 Reduced 48.63%	256,028 $2.36 Million
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $97,835 - $194,162	-10,055 Reduced 1.98%	498,431 $8.53 Million
Q3 2019 Nov 14, 2019	BUY	$10.15 - $16.89 $4.6 Million - $7.65 Million	452,729 Added 811.97%	508,486 $5.29 Million
Q2 2019 Aug 14, 2019	SELL	$14.6 - $20.6 $96,491 - $136,145	-6,609 Reduced 10.6%	55,757 $870,000
Q1 2019 May 15, 2019	BUY	$15.53 - $19.75 $66,018 - $83,957	4,251 Added 7.31%	62,366 $0
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $1.49 Million - $2.72 Million	-95,657 Reduced 62.21%	58,115 $967,000
Q3 2018 Nov 13, 2018	SELL	$25.99 - $30.6 $616,534 - $725,893	-23,722 Reduced 13.36%	153,772 $0
Q2 2018 Aug 10, 2018	BUY	$27.78 - $38.53 $4.11 Million - $5.7 Million	147,961 Added 501.0%	177,494 $0
Q1 2018 May 11, 2018	SELL	$27.78 - $35.19 $629,689 - $797,651	-22,667 Reduced 43.42%	29,533 $931,000
Q4 2017 Feb 09, 2018	BUY	$23.33 - $35.01 $913,929 - $1.37 Million	39,174 Added 300.74%	52,200 $1.52 Million
Q3 2017 Nov 09, 2017	BUY	$21.65 - $32.18 $282,012 - $419,176	13,026	13,026 $371,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

10.2M

Call Options Held

5.9K

Put Options Held

1.4K

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71.9M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account